glp-1-based therapy therapies for diabetes, obesity and beyond Insights into incretin-based therapies for

Exogenous L-carnitine ameliorates burn-induced cellular and mitochondrial injury of hepatocytes by restoring CPT1 activity

No unexpected safety issues emerged over four years of continuous use

Eventually, the weight plateaued and actually increased thereafter, which mitigated the overall weight loss Weight Stigma, Weight Loss Medications, and Eating Disorders GLP-1s intensify discussions about weight loss that cause many living in larger bodies to express a sense of hopelessness in fat-focused conversations It is time to consider how to handle significant numbers of clients coming into eating disorder treatment programs on GLP-1s Clinicians need to consider what clients have been through with societal impact and weight stigma when making the ultimate decision regarding these medications

Comparison Between Established and the Worldwide Esophageal Cancer Collaboration Staging Systems

Tirzepatide while breastfeeding: what the newer data shows Tirzepatide has less published data than semaglutide but the existing evidence points in the same direction

Neuroendocrine peptides of the gut and their role in the regulation of food intake